Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 2046-2053

  Brown, Karen T ^a,c   Do, Richard K ^a,c   Gonen, Mithat ^a   Covey, Anne M ^a,c   Getrajdman, George I ^a,c   Sofocleous, Constantinos T ^a,c   Jarnagin, William R ^a,c   D'Angelica, Michael I ^a,c   Allen, Peter J ^a,c   Erinjeri, Joseph P ^a,c   Brody, Lynn A ^a,c   O'Neill, Gerald P ^a   Johnson, Kristian N ^a   Garcia, Alessandra R ^a   Beattie, Christopher ^a   Zhao, Binsheng ^b   Solomon, Stephen B ^a,c   Schwartz, Lawrence H ^b   DeMatteo, Ronald ^a,c   Abou Alfa, Ghassan K ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; MICROSPHERE; ANTINEOPLASTIC ANTIBIOTIC;

AGED; ARTERIAL EMBOLIZATION; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHOLECYSTITIS; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; FEMALE; FEVER; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREATITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED STUDY; LIVER NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VASCULARIZATION;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; SINGLE-BLIND METHOD;

EID: 84966615868     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.0821     Document Type: Article

References (30)

1. Llovet JM, Real MI, Montaña X, et al; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359:1734-1739, 2002
2. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002
3. Brown DB, Geschwind JF, Soulen MC, et al: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17:217-223, 2006
4. Meyer T, Kirkwood A, Roughton M, et al: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 108:1252-1259, 2013
5. Bruix J, Sherman M, Llovet JM, et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35:421-430, 2001
6. Llovet JM, Fuster J, Bruix J; Barcelona-Clínic Liver Cancer Group: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115-S120, 2004 (suppl 1)
7. Malagari K, Chatzimichael K, Alexopoulou E, et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: Results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:269-280, 2008
8. Lammer J, Malagari K, Vogl T, et al; PRECISION V Investigators: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41-52, 2010
9. Poon RT, Tso WK, Pang RW, et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100-1108, 2007
10. Aliberti C, Benea G, Tilli M, et al: Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results. Cardiovasc Intervent Radiol 31:883-888, 2008
11. Chrisman HB, Minocha J, Ryu RK, et al: Uterine artery embolization: A treatment option for symptomatic fibroids in postmenopausal women. J Vasc Interv Radiol 18:451-454, 2007
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
13. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60, 2010
14. Llovet JM, Di Bisceglie AM, Bruix J, et al; Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008
15. Vincenzi B, Di Maio M, Silletta M, et al: Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS One 10:e0133488, 2015
16. Brown DB, Gould JE, Gervais DA, et al;Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation: Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria. J Vasc Interv Radiol 20(7, Suppl)S425-S434, 2009
17. Namur J, Wassef M, Millot JM, et al: Drug-eluting beads for liver embolization: Concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 21:259-267, 2010
18. Namur J, Citron SJ, Sellers MT, et al: Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 55:1332-1338, 2011
19. Brown DB, Nikolic B, Covey AM, et al; Society of Interventional Radiology Standards of Practice Committee: Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287-294, 2012
20. Cammà C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 224:47-54, 2002
21. Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25, 2007
22. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al: Doxorubicin (75 mg/m2 ) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68:487-491, 1984
23. Lai CL, Wu PC, Chan GC, et al: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479-483, 1988
24. Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304:2154-2160, 2010
25. Malagari K, Pomoni M, Kelekis A, et al: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541-551, 2009
26. Lee KH, Liapi E, Vossen JA, et al: Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: Evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 19:1490-1496, 2008
27. Sahara S, Kawai N, Sato M, et al: Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 35:1363-1371, 2012
28. Dhanasekaran R, Kooby DA, Staley CA, et al: Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101:476-480, 2010
29. Lencioni R, Zou J, Leberre M, et al: Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol 28:15s, 2010 (abstr TPS178)
30. Kim S, Brown KT, Fong YM, et al: Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis. J Clin Oncol 32, 2014 (suppl 3; abstr 363)